Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients

Sum Lam, Julie L. Chen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The effects of equipotent doses of racemic albuterol and levalbuterol on heart rate (HR) in intensive care patients with and without baseline tachycardia were studied. Patients were included if they were hemodynamically stable and required bronchodilator therapy every four hours; patients were excluded if they were maintained on a β-blocker. Four hours after the most recent bronchodilator treatment, each patient was randomized to receive at least two consecutive doses of albuterol 2.5 mg or levalbuterol 1.25 mg four hours apart via nebulization. HR was recorded at the end of the second dose and 5, 10, 15, 30, 60, 90, 120, 180, and 240 minutes after treatment. Twenty intensive care patients, including 10 with baseline tachycardia and 10 without baseline tachycardia, were enrolled. In patients with baseline tachycardia, the mean largest HR increase was 1.4 beats/min (1.3%) with albuterol and 2.0 beats/min (2.1%) with levalbuterol (both increases were not significant). In patients without baseline tachycardia, the mean largest HR increase was 4.4 beats/min (6.7%) with albuterol (p = 0.04) and 3.6 beats/min (5.0%) with levalbuterol (p = 0.03). Short-term use of nebulized albuterol and levalbuterol was associated with similar changes in HR in intensive care patients with or without baseline tachycardia.

Original languageEnglish (US)
Pages (from-to)1971-1975
Number of pages5
JournalAmerican Journal of Health-System Pharmacy
Volume60
Issue number19
StatePublished - Oct 1 2003

Fingerprint

Levalbuterol
Albuterol
Critical Care
Heart Rate
Tachycardia
Bronchodilator Agents
Therapeutics

Keywords

  • Albuterol
  • Critical illness
  • Drug comparisons
  • Heart rate
  • Levalbuterol
  • Sympathomimetic agents
  • Tachycardia

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients. / Lam, Sum; Chen, Julie L.

In: American Journal of Health-System Pharmacy, Vol. 60, No. 19, 01.10.2003, p. 1971-1975.

Research output: Contribution to journalArticle

@article{ae07f3ed6c944d06974c04e574eaeafa,
title = "Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients",
abstract = "The effects of equipotent doses of racemic albuterol and levalbuterol on heart rate (HR) in intensive care patients with and without baseline tachycardia were studied. Patients were included if they were hemodynamically stable and required bronchodilator therapy every four hours; patients were excluded if they were maintained on a β-blocker. Four hours after the most recent bronchodilator treatment, each patient was randomized to receive at least two consecutive doses of albuterol 2.5 mg or levalbuterol 1.25 mg four hours apart via nebulization. HR was recorded at the end of the second dose and 5, 10, 15, 30, 60, 90, 120, 180, and 240 minutes after treatment. Twenty intensive care patients, including 10 with baseline tachycardia and 10 without baseline tachycardia, were enrolled. In patients with baseline tachycardia, the mean largest HR increase was 1.4 beats/min (1.3{\%}) with albuterol and 2.0 beats/min (2.1{\%}) with levalbuterol (both increases were not significant). In patients without baseline tachycardia, the mean largest HR increase was 4.4 beats/min (6.7{\%}) with albuterol (p = 0.04) and 3.6 beats/min (5.0{\%}) with levalbuterol (p = 0.03). Short-term use of nebulized albuterol and levalbuterol was associated with similar changes in HR in intensive care patients with or without baseline tachycardia.",
keywords = "Albuterol, Critical illness, Drug comparisons, Heart rate, Levalbuterol, Sympathomimetic agents, Tachycardia",
author = "Sum Lam and Chen, {Julie L.}",
year = "2003",
month = "10",
day = "1",
language = "English (US)",
volume = "60",
pages = "1971--1975",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "19",

}

TY - JOUR

T1 - Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients

AU - Lam, Sum

AU - Chen, Julie L.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - The effects of equipotent doses of racemic albuterol and levalbuterol on heart rate (HR) in intensive care patients with and without baseline tachycardia were studied. Patients were included if they were hemodynamically stable and required bronchodilator therapy every four hours; patients were excluded if they were maintained on a β-blocker. Four hours after the most recent bronchodilator treatment, each patient was randomized to receive at least two consecutive doses of albuterol 2.5 mg or levalbuterol 1.25 mg four hours apart via nebulization. HR was recorded at the end of the second dose and 5, 10, 15, 30, 60, 90, 120, 180, and 240 minutes after treatment. Twenty intensive care patients, including 10 with baseline tachycardia and 10 without baseline tachycardia, were enrolled. In patients with baseline tachycardia, the mean largest HR increase was 1.4 beats/min (1.3%) with albuterol and 2.0 beats/min (2.1%) with levalbuterol (both increases were not significant). In patients without baseline tachycardia, the mean largest HR increase was 4.4 beats/min (6.7%) with albuterol (p = 0.04) and 3.6 beats/min (5.0%) with levalbuterol (p = 0.03). Short-term use of nebulized albuterol and levalbuterol was associated with similar changes in HR in intensive care patients with or without baseline tachycardia.

AB - The effects of equipotent doses of racemic albuterol and levalbuterol on heart rate (HR) in intensive care patients with and without baseline tachycardia were studied. Patients were included if they were hemodynamically stable and required bronchodilator therapy every four hours; patients were excluded if they were maintained on a β-blocker. Four hours after the most recent bronchodilator treatment, each patient was randomized to receive at least two consecutive doses of albuterol 2.5 mg or levalbuterol 1.25 mg four hours apart via nebulization. HR was recorded at the end of the second dose and 5, 10, 15, 30, 60, 90, 120, 180, and 240 minutes after treatment. Twenty intensive care patients, including 10 with baseline tachycardia and 10 without baseline tachycardia, were enrolled. In patients with baseline tachycardia, the mean largest HR increase was 1.4 beats/min (1.3%) with albuterol and 2.0 beats/min (2.1%) with levalbuterol (both increases were not significant). In patients without baseline tachycardia, the mean largest HR increase was 4.4 beats/min (6.7%) with albuterol (p = 0.04) and 3.6 beats/min (5.0%) with levalbuterol (p = 0.03). Short-term use of nebulized albuterol and levalbuterol was associated with similar changes in HR in intensive care patients with or without baseline tachycardia.

KW - Albuterol

KW - Critical illness

KW - Drug comparisons

KW - Heart rate

KW - Levalbuterol

KW - Sympathomimetic agents

KW - Tachycardia

UR - http://www.scopus.com/inward/record.url?scp=1542649466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542649466&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 1971

EP - 1975

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 19

ER -